Who is sponsoring NCT04609813?

NCT04609813 is sponsored by Changhai Hospital.

What drugs are being tested in NCT04609813?

Interventions in NCT04609813: Sponge cytological test.

What condition does NCT04609813 study?

NCT04609813 studies Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma.

Is NCT04609813 still recruiting?

NCT04609813 is currently completed. Last updated 21 September 2022.

Last reviewed 2022-09-21 · How we verify

NCT04609813: EAST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Esophageal cAncer Screening Trial

Completed Last updated 21 September 2022

What this trial tests

trial testing Sponge cytological test in Esophageal Squamous Cell Carcinoma in 14,597 participants. Completed in 30 June 2022.

Timeline

1 January 2021

Primary endpoint
30 June 2022

30 June 2022

Quick facts

Lead sponsor	Changhai Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	14,597
Start date	1 January 2021
Primary completion	30 June 2022
Estimated completion	30 June 2022
Sites	1 location across China

Drugs / interventions tested

Sponge cytological test

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →
Esophageal Cancer — all drugs for Esophageal Cancer →
Gastroesophageal Junction Adenocarcinoma — all drugs for Gastroesophageal Junction Adenocarcinoma →

Sponsor

Changhai Hospital

Who can join

Adults 40 to 75, any sex, with Esophageal Squamous Cell Carcinoma or Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter study aims to include 15000 participants undergoing screening upper gastrointestinal endoscopy and establish a risk prediction model for esophageal squamous cell carcinoma and esophagogastric junctional (EGJ) adenocarcinoma in high-risk areas. The prediction model will be built based on epidemiological and cytological features, acquired from the esophageal sponge cytology test. The primary study outcome is the diagnostic performance of the model to detect high-grade lesions (including carcinoma and high-grade intraepithelial neoplasia) of the esophagus and EGJ. Secondary outcomes include the number needed to screen, and dignostic performance of cytologist under AI assistance and abnornal cell count.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Application of Esophageal Sponge Cytology in Screening Esophageal Squamous Cell Carcinoma in a High-Risk Region of China.
Huang S, Gu X, Zhou H, Feng Y, et al · · 2025 · cited 1× · PMID 39856802 · DOI 10.1002/cam4.70467
Development and Validation of a Score-Based Model for Estimating Esophageal Squamous Cell Carcinoma and Precancerous Lesions Risk in an Opportunistic Screening Population.
Bian Y, Gao Y, Jiang H, Li Q, et al · · 2025 · PMID 40647436 · DOI 10.3390/cancers17132138

Verify or expand the search:

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other Changhai Hospital trials

Trials by the same sponsor.

NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04609813 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
Last refreshed: 21 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04609813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing